Paper15531908
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
Gibo J and 8 others. Lab Invest, 2005. Cited by 79 papers, by iCite.
Cite this record
ConductScience Library. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Papers, record 15531908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15531908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fibrosis | Major topic |
| Gabexate | Major topic |
| Monocytes | Major topic |
| Pancreas | Major topic |
| Pancreatitis | Major topic |
| Protease Inhibitors | Major topic |
| Animals | |
| Cell Proliferation | |
| Chemokine CCL2 | |
| Disease Models, Animal | |
| Dose-Response Relationship, Drug | |
| Esters | |
| Guanidines | |
| Male | |
| Organotin Compounds | |
| Procollagen | |
| RNA, Messenger | |
| Rats | |
| Rats, Inbred Lew | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40973081 | Large Library Docking and Biophysical Analysis of Small-Molecule TMPRSS2 Inhibitors. | J Med Chem | 2025 | https://conductscience.org/library/papers/40973081 | PubMed |
| 40227431 | Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation. | Pediatr Cardiol | 2026 | https://conductscience.org/library/papers/40227431 | PubMed |
| 39858469 | TMPRSS2 as a Key Player in Viral Pathogenesis: Influenza and Coronaviruses. | Biomolecules | 2025 | https://conductscience.org/library/papers/39858469 | PubMed |
| 37081137 | Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. | Eur J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/37081137 | PubMed |
| 37059487 | Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. | J Pharmacol Sci | 2023 | https://conductscience.org/library/papers/37059487 | PubMed |
| 36857133 | Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. | J Med Chem | 2023 | https://conductscience.org/library/papers/36857133 | PubMed |
| 36515544 | A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/36515544 | PubMed |
| 35713329 | Tailored Phenyl Esters Inhibit ClpXP and Attenuate Staphylococcus aureus α-Hemolysin Secretion. | Chembiochem | 2022 | https://conductscience.org/library/papers/35713329 | PubMed |
| 35641023 | Drug repurposing for the treatment of COVID-19. | J Pharmacol Sci | 2022 | https://conductscience.org/library/papers/35641023 | PubMed |
| 35423713 | Immune response and possible therapeutics in COVID-19. | RSC Adv | 2020 | https://conductscience.org/library/papers/35423713 | PubMed |
| 35072549 | The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. | Expert Opin Drug Discov | 2022 | https://conductscience.org/library/papers/35072549 | PubMed |
| 34527443 | Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts. | PeerJ | 2021 | https://conductscience.org/library/papers/34527443 | PubMed |
| 34485853 | SARS-Cov-2: Biology, Detection, Macrophage Mediated Pathogenesis and Potential Treatments. | Virol Immunol J | 2020 | https://conductscience.org/library/papers/34485853 | PubMed |
| 34295715 | Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. | Cardiovasc Diagn Ther | 2021 | https://conductscience.org/library/papers/34295715 | PubMed |
| 33369210 | Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract. | Pharmacol Res Perspect | 2021 | https://conductscience.org/library/papers/33369210 | PubMed |
| 33290397 | Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. | PLoS Comput Biol | 2020 | https://conductscience.org/library/papers/33290397 | PubMed |
| 33234691 | Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. | Sci Signal | 2020 | https://conductscience.org/library/papers/33234691 | PubMed |
| 33225308 | Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. | Crit Care Explor | 2020 | https://conductscience.org/library/papers/33225308 | PubMed |
| 33112126 | Targeting Crucial Host Factors of SARS-CoV-2. | ACS Infect Dis | 2020 | https://conductscience.org/library/papers/33112126 | PubMed |
| 32693756 | Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. | Curr Med Chem | 2021 | https://conductscience.org/library/papers/32693756 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15531908
GET https://conductscience.org/api/papers/v1/15531908/cited_by?page=2